Elixirgen Therapeutics and Nippon Shinyaku Enter Option Agreement for Full-Length Dystrophin mRNA Therapy EXG-7001 in Duchenne Muscular Dystrophy
核心洞察
Elixirgen Therapeutics (搜索) and Nippon Shinyaku have entered into an option agreement granting Nippon Shinyaku potential exclusive worldwide commercialization rights to EXG-7001 for Duchenne muscular dystrophy (搜索).
EXG-7001 is a locally administered, full-length dystrophin (搜索) mRNA therapeutic currently in preclinical development, designed to deliver the complete dystrophin protein regardless of a patient's genetic mutation.
Nippon Shinyaku will fund developmental costs, while Elixirgen receives an upfront payment and is eligible for additional development and sales-based milestone payments if the option is exercised.
Elixirgen Therapeutics (搜索), Inc., a clinical-stage biotechnology company focused on rare diseases and aging-associated conditions, announced on June 26, 2026, that it has entered into an option agreement with Nippon Shinyaku Co., Ltd. for the development and commercialization of EXG-7001, a novel mRNA therapeutic candidate for Duchenne muscular dystrophy (搜索) (DMD). Under the terms of the agreement, Nippon Shinyaku may obtain exclusive worldwide rights to commercialize EXG-7001, while Elixirgen retains responsibility for its development.
The financial structure of the deal includes an upfront payment to Elixirgen, with the company also eligible to receive additional development and sales-based milestone payments should Nippon Shinyaku exercise its option rights. Nippon Shinyaku will provide funding for the developmental costs. Upon exercise of the option and subsequent regulatory approval in the United States, NS Pharma (搜索), Inc., a wholly owned subsidiary of Nippon Shinyaku based in New Jersey, will handle marketing and commercialization of EXG-7001.
A Differentiated Approach to Dystrophin (搜索) Restoration
EXG-7001 is a locally administered, full-length dystrophin (搜索) mRNA therapeutic currently in preclinical development. Unlike existing therapeutic strategies, which according to Elixirgen CEO Aki Ko focus on "delivering or restoring an incomplete dystrophin protein," EXG-7001 is designed to deliver the full-length, complete dystrophin protein that is missing in DMD patients, regardless of their specific genetic mutation.
"By design, EXG-7001 has the potential to deliver the full-length, complete dystrophin (搜索) protein that is missing in DMD patients, regardless of their genetic mutation," said Aki Ko, Chief Executive Officer of Elixirgen Therapeutics (搜索). "We look forward to combining Elixirgen's clinical and regulatory excellence with Nippon Shinyaku's expertise and mission to improve the lives of those living with rare diseases."
Disease Background and Unmet Need
Duchenne muscular dystrophy (搜索) is a rare, progressive muscular dystrophy characterized by severe muscle wasting and weakness. The disease is caused by genetic mutations in the DMD gene, which result in the dysfunction or absence of the dystrophin (搜索) protein — a critical component for healthy muscle cell function. Current treatment approaches have been limited to restoring partial dystrophin function, leaving what Ko described as "a significant unmet need for a therapy that can successfully deliver a full-length dystrophin protein."
Strategic Rationale
The partnership pairs Elixirgen's proprietary mRNA platform technologies and ZSCAN4 technology with Nippon Shinyaku's established expertise in rare disease commercialization. Nippon Shinyaku, headquartered in Kyoto, Japan, operates under the business philosophy of "Helping people lead healthier, happier lives" and aims to bring unique medicines to patients and families suffering from illness.
Elixirgen Therapeutics (搜索), based in Baltimore, is a clinical-stage biotechnology company developing treatments for rare diseases and aging-associated diseases using its ZSCAN4 technology and mRNA platform technologies.